Analysts' Actions: ZNGA, DFS, ACN
TheStreet Staff
03/23/12 - 08:26 AM EDT
Aetna (AET) downgraded at Goldman from Buy to Neutral, Goldman Sachs said. Company is seeing limited growth prospects in the commercial health plan business. $54 price target.
Agrium (AGU) downgraded at JP Morgan from Overweight to Neutral, JP Morgan said. Valuation call, based on an $88 price target.
Cubist (CBST) rated new Buy at ThinkEquity. $50 price target. Company has both a solid base business and deep pipeline.
Coventry Health (CVH) upgraded at Goldman to Buy from Neutral, Goldman Sachs said. $42 price target. Company is building a larger footprint in public sector managed care.
Discover Financial (DFS) upgraded at Goldman from Neutral to Buy, Goldman Sachs said. Company also added to the Conviction List. $39 price target. Net interest margin should improve and the company can deliver better margin growth.
HCA (HCA) rated new Buy at Cantor. $30 price target. Earnings growth is accelerating.
Altria (MO) upgraded at Wells to Outperform from Market Perform, Wells Fargo said. Company should see its market share stabilize.
Monster Worldwide (MWW) upgraded at Baird from Neutral to Outperform, Robert Baird said. Risk/reward has improved at current levels. $15 price target.
Reynolds American (RAI) downgraded at Wells from Outperform to Market Perform, Wells Fargo said. Company will likely use promotions to defend market share at Pall Mall.
US Silica (SLCA) rated new Buy at BofA/Merrill. $25 price target. Company is the only pure play in the tight frac sand market.
Volcano Corp. (VOLC) upgraded at Jefferies to Buy from Hold, Jefferies said. $37 price target. Rare story in medical devices that checks all the boxes.
Xilinx (XLNX) downgraded at Auriga from Buy to Hold, Auriga said. $39 price target. Company will be hurt by continued carrier weakness.
Zynga (ZNGA) rated new Underperform at Needham. Growth will likely decelerate.
STOCK COMMENTS / EPS CHANGES
Accenture (ACN) target raised at Jefferies to $63, Jefferies said. Strong outsourcing results continue. Hold rating.
Accenture numbers raised at Citigroup. Shares of ACN now seen reaching $73, according to Citigroup. Estimates also increased on strong quarter and unwarranted demand concern. Buy rating.
Accenture estimates, target raised at Morgan Stanley. Shares of ACN now seen reaching $75, according to Morgan Stanley. Estimates also increased, as the company is gaining market share. Overweight rating.
Baker Hughes (BHI) numbers cut at UBS. Shares of BHI now seen reaching $60, according to UBS. Estimates also lowered on lower utilization, costs, and pricing. Buy rating.
Baker Hughes numbers cut at Credit Suisse. Shares of BHI now seen reaching $56, according to Credit Suisse. Estimates also reduced, given the company's new guidance. Outperform rating.
Cerner (CERN) price target raised at UBS to $80, UBS said. Strong 2011 bookings and continued tailwinds from HITECH. Neutral rating.
Dollar General (DG) numbers upped at BMO. DG estimates were boosted through 2013, BMO Capital said. Company is buying back more stock. Outperform rating and new $55 price target.
Foot Locker (FL) numbers increased at BofA/Merrill. FL estimates were raised through 2014, Bank of America/Merrill Lynch. Estimates also raised, given higher retail shoe demand. Buy rating and new $40 price target.
No comments:
Post a Comment